Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-3 CANCELED

4. (previously presented) A compound comprising the structure of formula I: wherein:



- Ring A is optionally substituted with one to five substituents selected from
  a) a C_1, C_2, C_3, C_4 or C_5 branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy; or
  b) a halogen or trihaloalkyl;

- Ring B comprises at least one structure denoted by R_a and R_b which represent an *ortho*-quinone moiety (-(C=O)-(C=O)-), *ortho*-catechol (-(C-OH)-(C-OH)-) or *ortho*-catechol pro-drug moiety (-(C-O-Prodrug moiety)-(C-O-Prodrug moiety)-); and the remaining carbons of Ring B are optionally substituted with one to five substituents selected from
  a) a C_1, C_2, C_3, C_4 or C_5 branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;
  b) a halogen or trihaloalkyl;
  c) a C_1, C_2, C_3, C_4 or C_5 branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy; or
  d) an OH, or a C_1, C_2, C_3, C_4 or C_5 primary, secondary, or tertiary alcohol;

e) nitro; and

- Bridge X is an alkene (-CR_9=CR_{10}-), wherein R_9 and R_{10} are alternatively H, alkyl, amino, amido, cyano, hydroxyl, or carboxyl;

provided that said compound is not combretastatin A1 or a salt, ester, or prodrug thereof.

Claims 5 - 9 CANCELED

10. (currently amended) A compound comprising a quinone, quinone prodrug, or a pharmaceutically acceptable salt form thereof having one of the following general structures:

IIa:



or

IIb:



wherein:

a. ~~at least one of~~ R_1, R_2, R_3, R_4, R_5, R_6, R_7 ~~or~~ and R_8 are the same or different and are selected from:

i) a C_1, C_2, C_3, C_4 or C_5 branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;

ii) a halogen or trihaloalkyl;

iii) a C_1, C_2, C_3, C_4 or C_5 branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy; or

iv) ~~an OH, or~~ a C_1, C_2, C_3, C_4 or C_5 primary, secondary, or tertiary alcohol; ~~or~~

and the remaining R_1, R_2, R_3, R_4, R_5, R_6, R_7, or R_8 are H; and

b. X is an alkene (-CR_9=CR_{10}-), wherein R_9 and R_{10} are alternatively H, alkyl, amino, amido, cyano, hydroxyl, or carboxyl

provided that said compound is not combretastatin A1 or a salt, ester, or prodrug thereof.

11. (canceled)

12. (currently amended) The compound of claim ~~11~~ 10, wherein X is an ethylene group (-CH=CH-), and Rings A and B are in a cis (Z) isomeric configuration.

13. (original) The compound of claim 12, wherein R_2, R_3 and R_4 are methoxy.

14. (previously presented) The compound of claim 13, wherein R_8 is selected from:

i) a C_1, C_2, C_3, C_4 or C_5 branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;

ii) a halogen or trihaloalkyl;

iii) a C_1, C_2, C_3, C_4 or C_5 branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy;

iv) an OH, or a C_1, C_2, C_3, C_4 or C_5 primary, secondary, or tertiary alcohol; or

v) nitro;

and the remaining R_1, R_5, R_6, and R_7 are H.

15. (original) The compound of claim 14, wherein R_8 is OH or –O-CH_2-CH=CH_2.

16. (original) The compound of claim 4, wherein said catechol is a biooxidative agent which is oxidatively activated *in vivo* to form a quinone capable of participating in a redox cycling reaction to form one or more Reactive Oxygen Species ("ROS").

Claims 17-33 CANCELED

34. (currently amended) A composition of the following formula (V):



(V)

wherein

a. Z is an ethylene (-CH=CH-) bridge in the cis (Z) isomeric configuration;

b. R_1 and R_2 are OH or a prodrug form thereof;

c. ~~at least one of~~ R_3, R_4, R_5, R_6, R_7, R_8, and R_9 are ~~optionally~~ the same or different and selected from

i) a C_1, C_2, C_3, C_4 or C_5 branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;

ii) a halogen or trihaloalkyl;

iii) a C_1, C_2, C_3, C_4 or C_5 branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy; or

iv) ~~an OH, or~~ a C_1, C_2, C_3, C_4 or C_5 primary, secondary, or tertiary alcohol;

v) nitro; and

the remaining R_3, R_4, R_5, R_6, R_7, R_8 and R_9 are hydrogen,

provided that said compound is not combretastatin A1 or prodrug thereof.

35. (original) The composition of claim 34, wherein at least three of R_6, R_7, R_8, and R_9 are not hydrogen.

36. (original) The composition of claim 35, wherein R_6, R_7 and R_8 are the same.

37. (original) The composition of claim 36, wherein R_6, R_7 and R_8 are methoxy.

38. (currently amended) The composition of claim 37, wherein R_3 is

i) a C_1, C_2, C_3, C_4 or C_5 branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;

ii) a halogen or trihaloalkyl;

iii) a C_1, C_2, C_3, C_4 or C_5 branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy;

iv) an OH, or a C_1, C_2, C_3, C_4 or C_5 primary, secondary, or tertiary alcohol; or

~~vi~~ v) oxo, lower alkanoyl, thio, sulfonyl, sulfonamide, nitro, nitrosyl, cyano, carboxy, carbamyl, aryl, or heterocycle; and

R_4, R_5, and R_9 are hydrogen.

39. (previously presented) The composition of claim 38, wherein R_3 is $-CH_3$, $-CH_2CH_3$, $-OCH_2CH_3$, -F, -Br, $-CF_3$, $-CBr_3$, -OH, $-O-CH_2-CH=CH_2$, $-CH_2-CH=CH_2$, $-NO_2$, -cyano, or -carboxy.

40. (original) The composition of claim 39, wherein R_6, R_7, and R_8 are F.

41. (currently amended) The composition of claim 40, wherein R_3 is

i) a C_1, C_2, C_3, C_4 or C_5 branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;

ii) a halogen or trihaloalkyl;

iii) a C_1, C_2, C_3, C_4 or C_5 branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy;

iv) an OH, or a C_1, C_2, C_3, C_4 or C_5 primary, secondary, or tertiary alcohol;

~~vi~~ v) oxo, lower alkanoyl, thio, sulfonyl, sulfonamide, nitro, nitrosyl, cyano, carboxy, carbamyl, aryl, or heterocycle; and

R_4, R_5, and R_9 are hydrogen.

42. (previously presented) The composition of claim 41, wherein R_3 is $-CH_3$, $-CH_2CH_3$, $-OCH_2CH_3$, -F, -Br, $-CF_3$, $-CBr_3$, -OH, $-O-CH_2-CH=CH_2$, $-CH_2-CH=CH_2$, $-NO_2$, -cyano, -carboxy, or –benzyl.

Claims 43-56 CANCELED

57. (original) A composition selected from the group consisting of
6-[(Z)-2-(3,4,5-Trimethoxyphenyl) vinyl]-1,2-dihydroxybenzene,
3-Ethyl-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1 ,2-dihydroxybenzene,
3-Methyl-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,
4-Bromo-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,
4-Phenyl-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,
3-Allyl-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,
4-Fluoro-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,
2,3,4-Trihydroxy-6-[(Z)-2(3,4,5-trimethoxyphenyl)vinyl]-benzene,
2,3-Dihydroxy-4-ethoxy-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-benzene,
2,3-Dihydroxy-4-allyloxy-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-benzene,
4-Nitro-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-2,3-dihydroxybenzene,
2',3'dihydroxy -3,5 dichloro4,4'-dimethoxy-(Z)-stilbene,
2',3' dihydroxy-4'-methoxy-3,4,5-trifluoro-(Z)-stilbene,
2,3-Dihydroxy-4-methoxy-[(Z)-2-(3,4,5-trimethoxyphenyl) Beta-lactam]-benzene,
2',3' diphosphate-3,4,5-trimethoxy-(Z)-stilbene, tetrasodium salt;
3',4' diphosphate-3,4,5-trimethoxy-(Z)-stilbene, tetrasodium salt;
and combinations thereof.

58.(previously presented) The compound of claim 4, wherein X is an ethylene group (-CH=CH-), and Rings A and B are in a cis (Z) isomeric configuration